Initial patient, brachial cleft cyst, and treatment characteristics and changes in the cysts (before versus after ethanol ablation)
| Patient | Sex | Age (yr) | Index Volume (mL) | Aspiration Volume (mL) | Ethanol Volume (mL) | Treatment Sessions (No.) | Fluid Volume (mL) at Follow-Up | VRR (%) | Therapeutic Success | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1–2 mo (n = 17) | 3–6 mo (n = 9) | 7–12 mo (n = 7) | Final Evaluation (n = 15) | |||||||||
| 1 | M | 17 | 29.4 | 30.0 | 10 | 2 | 57.9a | 0.4 (14) | 98.6 | Yes | ||
| 2 | F | 13 | 3.8 | 3.0 | 2 | 2 | 1.1 | 4.4a | 0.3 | 0.3 (8) | 92.1 | Yes |
| 3 | M | 33 | 41.4 | 40.0 | 20 | 2 | 35.6a | 2.4 | NA | 2.4 (4) | 94.2 | Yes |
| 4 | M | 15 | 36.6 | 36.0 | 10 | 2 | 33.7a | 9.7 | 1.2 | 0.1 (25) | 99.7 | Yes |
| 5 | M | 30 | 49.9 | 50.0 | 20 | 1 | NA | NA | NA | NA (12) | NA | Yes |
| 6 | F | 60 | 6.1 | 5.8 | 4 | 1 | 0.2 | 0.2 | 0.0 (18) | 100.0 | Yes | |
| 7 | F | 38 | 38.2 | 20.0 | 10 | 2 | 6.6a | NA | NA | NA (12) | NA | Yes |
| 8 | F | 25 | 38.0 | 21.0 | 10 | 6 | 5.7a/25.12a | 30.4a/9.3a | 2.2 | 0.5 (16) | 98.7 | Yes |
| 9 | M | 6 | 12.4 | 12.0 | 4 | 1 | NA | NA | NA | NA (22) | NA | Yes |
| 10 | M | 37 | 42.2 | 31.0 | 10 | 2 | 15.1a | 1.2 | 0.3 | 0.3 (12) | 99.3 | Yes |
| 11 | M | 41 | 7.5 | 7.0 | 7 | 2 | 7.4a | NA | NA | NA (12) | NA | Yes |
| 12 | F | 26 | 11.8 | 12.0 | 5 | 1 | 1.4 | 0.4 | NA | 0.4 (6) | 96.6 | Yes |
| 13 | F | 49 | 32.8 | 30.0 | 10 | 1 | 0.8 | NA | NA | 0.8 (2) | 97.6 | Yes |
| 14 | F | 34 | 37.7 | 15.0 | 10 | 2 | 30.3a | NA | NA | NA (12) | NA | Yes |
| 15 | F | 22 | 48.1 | 33.0 | 25 | 3 | 116.1a | 86.4a | 2.5 | 2.5 (9) | 94.8 | Yes |
| 16 | F | 25 | 13.9 | 10.0 | 6 | 2 | 13.0a | 4.3a | 2.2 | 2.2 (7) | 84.2 | Yes |
| 17 | F | 32 | 5.5 | 5.0 | 4 | 1 | 1.1 | NA | NA | 1.1 (1) | 80.0 | Yes |
| 18 | F | 72 | 25.1 | 17.0 | 20 | 1 | 3.5 | NA | NA | 3.5 (1) | 86.1 | Yes |
| 19 | M | 2 | 37.6 | 36.0 | 10 | 1 | 0.7 | NA | NA | 0.7 (2) | 98.1 | Yes |
| 20 | F | 38 | 10.6 | 10.0 | 6 | 1 | 2.6 | NA | NA | 2.6 (2) | 75.5 | Yes |
| Mean | 30.8 ± 17.0 | 26.4 ± 15.7 | 21.2 ± 13.6 | 10.2 ± 6.3 | 1.8 ± 1.2 | 17.3 ± 28.3 | 15.5 ± 28.2 | 9.5 ± 21.4 | 1.2 ± 1.1 | 93.0 ± 7.9 | ||
Note:—VRR indicates volume reduction rate; NA, not available.
↵a Additional EA treatment during the follow-up period. The clinical follow-up duration for each patient is shown in parentheses.